BioTime Inc. (NYSE:BTX) touted today positive preclinical results for its HyStem hydrogel drug-delivery technology, demonstrating that targeted intracerebral delivery of brain-derived neurotrophic factor may alleviate the effects of ischemic brain injury and reduce neuroinflammation. The study, published in the International Journal of Molecular Sciences, focused on the effects of BDNF on sensorimotor function, infarct volume and neuroinflammation […]
BioTime lands $1.9m grant to fund dry-AMD drug
BioTime Inc. (NYSE:BTX) said today that it won a $1.9 million grant from the Israel Innovation Authority to help support development of its dry-AMD drug, OpRegen. The company’s investigational therapy delivers retinal pigment epithelial cells into the subretinal space to replace lost RPE cells in patients with macular degeneration. BioTime is testing its drug in a […]
BioTime raises $29m in public offering
BioTime Inc. (NYSE:BTX) has closed its public offering of 9,615,385 shares of common stock, the company said today, raising nearly $29 million. The Alameda, Calif.-based company said it plans to use the offering’s net proceeds to support clinical trials, R&D activities and for other general corporate purposes. In August, BioTime announced that its subsidiary, Cell Cure Neurosciences, […]
BioTime expands OpRegen dry-AMD trial with U.S. sites
BioTime Inc. (NYSE:BTX) said today that it expanded its OpRegen Phase I/IIa trial into the U.S. with 2 new trial sites. The company’s study is evaluating its OpRegen cell therapy in patients with advanced dry form age-related macular degeneration. The 2 U.S.-based trial sites will include ophthalmologists Dr. David Boyer from the Retina-Vitreous Associates Medical Group […]
BioTime and subsidiary establish cell manufacturing facility in Israel
BioTime Inc. (NYSE:BTX) and its subsidiary Cell Cure Neurosciences said today that it is establishing an 800 square meter cell manufacturing facility at the Hadassah University Hospital in Jerusalem. The manufacturing center will be staffed initially by 30 employees, according to the companies, and will be prepared to produce OpRegen for BioTime’s ongoing clinical trial […]
